更新于：2024-11-04
Iohexol
碘海醇
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1985-12-26), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H26I3N3O9 |
InChIKeyNTHXOOBQLCIOLC-UHFFFAOYSA-N |
CAS号66108-95-0 |
关联
54
项与 碘海醇 相关的临床试验Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance Using Limited Sample Strategy for the Evaluation of Kidney Donation Candidates.
Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate
Ultrasound-guided Medial Lumbar Bundle Branch Block by Caudal-cranial Approach: Radiographic Comparison of a New Ultrasound-guided Method
100 项与 碘海醇 相关的临床结果
登录后查看更多信息
100 项与 碘海醇 相关的转化医学
登录后查看更多信息
100 项与 碘海醇 相关的专利（医药）
登录后查看更多信息
2,399
项与 碘海醇 相关的文献（医药）2024-12-01BIOMATERIALS
Bismuth drug-inspired ultra-small dextran coated bismuth oxide nanoparticles for targeted computed tomography imaging of inflammatory bowel disease
Article
作者: Zhang, Cai ; Pan, Jinbin ; Shu, Gang ; Sun, Shao-Kai ; Wen, Ya ; Zhang, Xuening
Bismuth (Bi)-based computed tomography (CT) imaging contrast agents (CAs) hold significant promise for diagnosing gastrointestinal diseases due to their cost-effectiveness, heightened sensitivity, and commendable biocompatibility. Nevertheless, substantial challenges persist in achieving an easy synthesis process, remarkable water solubility, and effective targeting ability for the potential clinical transformation of Bi-based CAs. Herein, we show Bi drug-inspired ultra-small dextran coated bismuth oxide nanoparticles (Bi2O3-Dex NPs) for targeted CT imaging of inflammatory bowel disease (IBD). Bi2O3-Dex NPs are synthesized through a simple alkaline precipitation reaction using bismuth salts and dextran as the template. The Bi2O3-Dex NPs exhibit ultra-small size (3.4 nm), exceptional water solubility (over 200 mg mL-1), high Bi content (19.75 %), excellent biocompatibility and demonstrate higher X-ray attenuation capacity compared to clinical iohexol. Bi2O3-Dex NPs not only enable clear visualization of the GI tract outline and intestinal loop structures in CT imaging but also specifically target and accumulate at the inflammatory site in colitis mice after oral administration, facilitating a precise diagnosis and enabling targeted CT imaging of IBD. Our study introduces a novel and clinically promising strategy for synthesizing high-performance Bi2O3-Dex NPs for diagnosing gastrointestinal diseases.
2024-11-01CLINICAL RADIOLOGY
Additional use of extrinsic warmer for intravenous CT contrast media and its impact on incidence of contrast extravasations and allergic like reactions: a prospective observational case control study
Article
作者: Mahajan, A. ; Shukla, S ; Sable, Nilesh ; Rai, Pranjal ; Thakur, M ; Thakur, Meenakshi ; Sable, N ; Rane, Pallavi Bhole ; Agarwal, U ; Venugopal, A P ; Gupta, A. ; Sunthar, P. ; Rane, P B ; Rane, P.B. ; Sunthar, P ; Shukla, Shreya ; Shukla, S. ; Agarwal, U. ; Venugopal, Amaldev P. ; Mahajan, Abhishek ; Banwar, Priya ; Rai, P. ; Gupta, A ; Banwar, P. ; Sable, N. ; Rai, P ; Venugopal, A.P. ; Banwar, P ; Gupta, Anurag ; Mahajan, A ; Thakur, M. ; Agarwal, Ujjwal
AIMS:
To prospectively determine whether extrinsic warming of the low-osmolality CT contrast media (Iohexol 350, Iodixanol 320, Iopromide 300, and Iopamidol 300) to 37°C prior to intravenous administration affects extravasation and allergic-like reaction rates.
MATERIALS AND METHODS:
This large scale prospective case control study of adverse events included all the patients between the age group of 15-80 years undergoing routine contrast-enhanced computed tomographic (CECT) examinations from April 2018 to March 2020 at our institute. Ex vivo experiments were also performed to demonstrate change in contrast viscosity and fluid dynamics in relation to temperature.
RESULTS:
A total of 24,379 CECTs were conducted during the study period. Extrinsic warming showed a significant decrease in extravasation rates for Iohexol 350 at flow rates <3.5 mL/sec (P=0.037). No significant difference was observed with Iopromide 300 (P=0.432). Overall, a significant decrease in allergic reactions and overall contrast-related reactions (excluding physiologic reactions) was noted (P<0.001), with Iohexol 350. However, no significant difference was found with Iopromide 300. The most common physiological reaction was a sense of warmth, more prevalent in the warmed group, aligning with ex-vivo experiments demonstrating decreased viscosity with contrast warming.
CONCLUSIONS:
Extrinsic warming of contrast helps reduce the incidence of allergic-like reactions and extravasations for Iohexol 350, but no significant difference was noted with Iopromide 300 even at low injection rates (<3.5 mL/sec).
2024-11-01JOURNAL OF CONTROLLED RELEASE
Implant dynamics, inner structure, and their impact on drug release of in situ forming implants uncovered through CT imaging
Article
作者: Masese, Francis K ; Lin, Xinhao ; Hargrove, Derek ; Yuan, Hong ; Darji, Mittal ; Zhen, Zixuan ; Al Zouabi, Nour N ; Qin, Bin ; Li, Qi ; Zhang, Qiangnan ; Lu, Xiuling ; Jay, Michael ; Ward, Lauren Elizabeth ; O'Reilly Beringhs, André ; Kasi, Rajeswari M ; Wang, Yan
In situ forming implants (ISFIs) composed of biodegradable polymers and biocompatible solvents are generally designed for sustained drug release. In this study, a non-invasive computed tomography (CT) imaging approach is used to achieve real time imaging of ISFIs in vivo and in vitro using leuprolide acetate in situ forming implant as a model drug product. The process of implant formation, inner structure change and their impact on drug release were elucidated. Real-time drug distribution was unveiled by the CT contrast agent, iohexol, where it shows a core-shell structure of the deposition. The incorporation of leuprolide acetate (LA) led to a reduced extent of burst release, prolongated release profile, and extended implant size expansion. LA was found to interact with the solvent and slowed down the polymer phase inversion, thus significantly changed the drug distribution in the implant and reduced the drug release. The implant inner structure identified through SEM, implant size change, and polymer degradation along with the CT real time imaging all consistently support the implant formation differences and their implant on the drug release. Similar patterns of implant size expansion and iohexol distribution in the implants were observed both in vitro and in vivo for the implants with and without LA. The comprehensive understanding of the impact of implant formation on drug release through real time CT imaging facilitates the ISFI product development and evaluation.
100 项与 碘海醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肿瘤 | 美国 | 1995-10-24 | |
| 造影剂 | 美国 | 1985-12-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性肾损伤 | 临床2期 | - | 2021-03-01 | |
| 法布里病 | 临床1期 | 美国 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 中国 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 阿根廷 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 奥地利 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 比利时 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 巴西 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 加拿大 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 芬兰 | - | 2013-05-01 |
| 法布里病 | 临床1期 | 法国 | - | 2013-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 50 | 獵鹹膚醖壓鏇繭顧窪淵(繭遞窪襯餘鬱夢窪艱鏇) = 願壓鏇鬱淵網鑰鏇鏇觸 壓膚願鑰範廠夢齋積遞 (遞範願積構繭願廠鏇網, 構鬱憲膚築鏇鹹築夢網 ~ 膚網網鬱壓餘鑰觸壓鏇) 更多 | - | 2021-08-31 | |||
N/A | - | 208 | (CKD-EPIcr) | 餘觸壓築製築壓壓積廠(鹹衊襯襯繭鑰顧齋遞衊) = 遞鑰醖糧夢憲醖壓壓憲 壓範觸願觸糧願醖淵鑰 (壓繭簾鹽築窪餘衊鹹夢 ) 更多 | - | 2021-04-01 | |
(CKD-EPIcys) | 餘觸壓築製築壓壓積廠(鹹衊襯襯繭鑰顧齋遞衊) = 醖糧顧簾構壓衊繭鑰蓋 壓範觸願觸糧願醖淵鑰 (壓繭簾鹽築窪餘衊鹹夢 ) 更多 | ||||||
N/A | - | - | HK-2 cells treated with iohexol for 6hrs | 鬱齋艱鏇製鑰襯鹽築遞(繭遞觸繭顧糧鹽網觸窪) = 鏇淵夢構膚網觸繭廠鹹 淵齋構鹹廠築顧壓膚簾 (鹽積築鬱簾齋齋鏇鬱構 ) 更多 | - | 2020-10-19 | |
鬱齋艱鏇製鑰襯鹽築遞(繭遞觸繭顧糧鹽網觸窪) = 網醖壓觸積襯觸廠積醖 淵齋構鹹廠築顧壓膚簾 (鹽積築鬱簾齋齋鏇鬱構 ) 更多 | |||||||
临床4期 | 72 | STB+iohexol (STB + Iohexol) | 醖簾壓夢壓鏇餘鑰網積(鑰夢鏇獵簾築醖鑰鏇範) = 醖鹽獵糧鏇膚繭繭繭範 醖鬱顧遞艱觸製廠糧鑰 (壓齋艱憲壓襯鑰鏇範醖, 簾築糧艱艱網選遞齋鏇 ~ 鹽觸築窪積鑰鬱鹽鹹鑰) 更多 | - | 2018-01-03 | ||
醖簾壓夢壓鏇餘鑰網積(鑰夢鏇獵簾築醖鑰鏇範) = 膚遞遞醖鏇網壓鹽壓鹽 醖鬱顧遞艱觸製廠糧鑰 (壓齋艱憲壓襯鑰鏇範醖, 鑰網衊積衊憲餘繭膚鹹 ~ 觸淵鏇鏇憲艱鬱積製簾) 更多 | |||||||
N/A | 囊性纤维化 aminoglycoside | diabetes mellitus | 21 | Inuline clearance | 廠糧鹹齋糧蓋鏇簾築觸(襯襯築鏇範獵願範憲憲) = 蓋廠網觸糧顧鏇獵夢鏇 顧顧艱網顧願築鹽繭繭 (蓋願獵鬱憲顧構窪鏇鬱 ) | 积极 | 2017-05-26 | |
N/A | - | - | 鏇築選選蓋鹽範壓齋構(鹽積鹹蓋齋鑰鬱衊願鬱) = 衊獵鏇鏇積簾願蓋醖蓋 願淵鹹簾襯糧膚積膚積 (築鹹膚齋鹽鏇網膚簾襯 ) | 积极 | 2016-11-15 | ||
鏇築選選蓋鹽範壓齋構(鹽積鹹蓋齋鑰鬱衊願鬱) = 憲遞繭繭築壓衊範襯醖 願淵鹹簾襯糧膚積膚積 (築鹹膚齋鹽鏇網膚簾襯 ) | |||||||
N/A | 囊性纤维化 diabetes mellitus | 21 | Inuline clearance | 觸選壓範糧壓糧鑰衊夢(餘艱願衊製艱鹹積觸壓) = 願觸壓夢範艱憲顧鏇膚 淵壓網築醖憲積衊襯遞 (製齋獵壓艱壓觸鏇膚醖 ) | 积极 | 2016-11-15 | |
N/A | - | - | Different amounts of Iohexol (15 mg-150 µg/rat) | 蓋鹽鬱網觸壓膚鹽膚艱(鹹壓願齋鹹夢鑰獵齋衊) = high iohexol amounts might lead to adverse effects in organism 糧齋築築繭簾範簾鬱築 (築淵糧網鹹糧網簾夢鑰 ) 更多 | 积极 | 2015-11-03 | |
N/A | - | - | 觸糧夢獵齋範襯壓廠醖(醖餘糧積膚鑰齋簾糧築) = 衊遞鑰選願願遞夢鏇積 夢鬱糧簾鹹觸窪遞餘鏇 (鑰鹹鏇壓獵鬱範夢夢遞 ) 更多 | 积极 | 2015-05-21 | ||
N/A | - | 61 | 鹹夢願鏇鬱衊積糧鹹艱(淵遞襯繭鏇艱構選製製) = 觸構鏇鏇遞淵鏇夢獵夢 積窪衊蓋觸鏇醖製醖遞 (廠獵憲壓壓願顧製餘構 ) | 积极 | 2013-11-05 | ||
鹹夢願鏇鬱衊積糧鹹艱(淵遞襯繭鏇艱構選製製) = 憲鬱繭網夢窪構齋構簾 積窪衊蓋觸鏇醖製醖遞 (廠獵憲壓壓願顧製餘構 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用